Research programme: haemophilia therapeutics - Takeda/Xenetic Biosciences
Alternative Names: Factor VIII - Xenetic Biosciences; LA rfVIII PSA; Long-acting blood clotting factors - Takeda/Xenetic Biosciences; Polysialylated blood coagulation factors - Takeda/Xenetic BiosciencesLatest Information Update: 28 Mar 2023
At a glance
- Originator Baxter International; Lipoxen Technologies
- Developer Takeda; Xenetic Biosciences
- Class Blood coagulation factors; Recombinant proteins
- Mechanism of Action Blood coagulation factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haemophilia
Most Recent Events
- 23 Mar 2023 Preclinical development in Haemophilia is ongoing in USA and European Union
- 28 Jan 2022 No recent reports of development identified for preclinical development in Haemophilia in European Union (Parenteral, Injection)
- 28 Jan 2022 No recent reports of development identified for preclinical development in Haemophilia in USA (Parenteral, Injection)